Joseph Stringer
Stock Analyst at Needham
(4.83)
# 431
Out of 4,376 analysts
595
Total ratings
45.7%
Success rate
23.6%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Maintained: Buy | $28 | $10.13 | +176.41% | 73 | Jun 1, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $105 | $74.48 | +40.98% | 40 | May 15, 2026 | |
| PLRX Pliant Therapeutics | Maintained: Hold | n/a | $1.15 | - | 33 | May 12, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $50 | $15.70 | +218.47% | 4 | May 11, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $170 | $129.16 | +31.62% | 29 | May 8, 2026 | |
| STOK Stoke Therapeutics | Maintained: Buy | $40 | $30.01 | +33.29% | 44 | May 8, 2026 | |
| ANNX Annexon | Maintained: Buy | $11 | $5.29 | +107.94% | 34 | May 8, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | $18 | $8.65 | +108.09% | 46 | May 7, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $110 | $47.36 | +132.26% | 40 | May 7, 2026 | |
| STTK Shattuck Labs | Maintained: Buy | $14 | $4.58 | +205.68% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $446.83 | - | 30 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $130 | $86.40 | +50.46% | 46 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $46 | $47.44 | -3.16% | 42 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $510 | $303.05 | +68.29% | 46 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.91 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.89 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.29 | n/a | 13 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $21.56 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $163.88 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $51.84 | n/a | 2 | Apr 28, 2021 |
Phathom Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $28
Current: $10.13
Upside: +176.41%
Ionis Pharmaceuticals
May 15, 2026
Maintained: Buy
Price Target: $105
Current: $74.48
Upside: +40.98%
Pliant Therapeutics
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $1.15
Upside: -
BioAge Labs
May 11, 2026
Maintained: Buy
Price Target: $50
Current: $15.70
Upside: +218.47%
Gilead Sciences
May 8, 2026
Maintained: Buy
Price Target: $170
Current: $129.16
Upside: +31.62%
Stoke Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $40
Current: $30.01
Upside: +33.29%
Annexon
May 8, 2026
Maintained: Buy
Price Target: $11
Current: $5.29
Upside: +107.94%
Vir Biotechnology
May 7, 2026
Maintained: Buy
Price Target: $18
Current: $8.65
Upside: +108.09%
Vaxcyte
May 7, 2026
Reiterated: Buy
Price Target: $110
Current: $47.36
Upside: +132.26%
Shattuck Labs
May 7, 2026
Maintained: Buy
Price Target: $14
Current: $4.58
Upside: +205.68%
May 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $446.83
Upside: -
May 5, 2026
Maintained: Buy
Price Target: $130
Current: $86.40
Upside: +50.46%
May 1, 2026
Maintained: Hold
Price Target: $46
Current: $47.44
Upside: -3.16%
Apr 30, 2026
Maintained: Buy
Price Target: $510
Current: $303.05
Upside: +68.29%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $1.91
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $2.89
Upside: n/a
Dec 23, 2022
Rated: Hold
Price Target: n/a
Current: $16.29
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $21.56
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $163.88
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $51.84
Upside: n/a